Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Dose-equivalence claims require direct comparative studies measuring relevant outcomes
Your Options Request a formulary exception your doctor can argue medical necessity What to do if Wegovy is not covered Cardiovascular risk reduction if you have heart disease risk factors, Wegovy's FDA-approved indication (March 2024) strengthens your case Consider Zepbound as of October 1, 2026 it returns as an "additional preferred option" alongside Wegovy on most Aetna/CVS Caremark plans [10] Zepbound coverage on Aetna Switch plans during open enrollment if your employer offers multiple options, check for GLP-1 coverage Explore self-pay options NovoCare ($349/mo) and patient assistance may help Wegovy Cost Guide About Wegovy's FDA Approvals Important: Sleep Apnea Coverage Goes to Zepbound, Not Wegovy Note: Zepbound (tirzepatide), not Wegovy, was FDA-approved to treat obstructive sleep apnea (OSA) in adults with obesity on December 20, 2024
When clinically appropriate, GLP-1 therapy can help lower cardiometabolic strain and inflammatory burden while complementing, not replacing, lifestyle fundamentals such as nutrient-dense eating, regular movement, resistance training, adequate protein intake, and restorative sleep
Chilton, Didcot, Oxfordshire: Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC (2018)
